Your SlideShare is downloading. ×
Social media
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Social media

279
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
279
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • http://www.novonordisk.com/images/about_us/changing-diabetes/frontimage.jpghttp://www.novonordisk-us.com/documents/article_page/document/Our_Values.asp
  • http://clinicaltrials.gov/ct2/show/NCT01028404
  • http://www.diabeticlive.com/diabetes-101/the-reasons-behind-missed-injections/#.Ts3A6rIk61c
  • http://www.mmm-online.com/novo-nordisk-refreshes-diabetes-online-presence-with-cornerstones4care/article/194553/
  • http://www.cornerstones4care.com/Index.aspx
  • http://forecast.diabetes.org/magazine/features/2011-software-applications-controlling-diabetes
  • Transcript

    • 1. “Our Actions Reflect Our Values” -Novo Nordisk Presented By: Shruti Dwivedi Abdul Al-Jazairi Roohee Peerzada
    • 2. Introduction• Company: Novo Nordisk®• Drug Name: NN1952 (No Name Assigned)• Indication: Oral replacement therapy for patients with Type 1 & Type 2 diabetes• Fast-acting oral insulin analogue. First phase 1study completed during the fourth quarter of 2010. – The first drug of its class – Potential Blockbuster – Novo Nordisk has a licensing deal with Merrion Pharmaceuticals – NN is using GIPET® technology by Merrion Pharms to develop the oral formulation – Deal: Merrion will get $54M for the first product to be launched – Have already received $2M as the drug progressed to Phase II
    • 3. Facts• More than 50% of all diabetics who must use insulin injections to manage their disease miss injections on a regular basis.• Why would someone intentionally bypass the use of medication that can help them in their personal health care?• The two of the most common reasons : – I am embarrassed – It is painful
    • 4. Our PlanTarget: Social Media Focus: Exposure
    • 5. Goal
    • 6. Website focused on Diabetics• We are launching an online support program for diabetes patients, dubbed Cornerstone4care that promises patients one-stop shopping for diabetes information and product information• They can also get recipes, calculate nutritional values, connect with other patients and get daily action plans tailored to their lifestyle and information needs, along with strategies for dealing with special situations like travel.• The site focuses on four “cornerstones” of diabetes control – checking blood sugar, eating healthy, exercising and taking medications
    • 7. Diabetes APP• We plan to develop a software for Diabetics which allows them to record, store, and analyze information electronically, all in the palm of your hand.• Features: – This app lets you record blood glucose levels and note the time of day—such as “before breakfast” or “during activity.” – You can view trend graphs, interact in the forums, and record insulin injections, exercise, and food eaten. – You can also sync your phone to an online account to manage your data on our website. – Easily downloadable to cell phones and computers – Compatible with almost every data network